EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Global Trends in CD4 Count Measurement and Distribution at First Antiretroviral Treatment Initiation

Reneé de Waal iD, Kara Wools-Kaloustian, Ellen Brazier iD, Keri N Althoff iD, Antoine Jaquet iD, Stephany N Duda iD, Nagalingeswaran Kumarasamy, Theodora Savory, Helen Byakwaga iD, Gad Murenzi iD, Amy Justice iD, Didier K Ekouevi und 19 weitere

Clinical Infectious Diseases · 18.07.2025 · 80 (6) · 1332-1336

DOI: 10.1093/cid/ciae548 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 06.11.2024. Verfasst von Reneé de Waal und 30 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Infectious Disease Epidemiology and Research, School of Public Health, University of Cape Town, Observatory, South Africa. Hauptthemen laut MEDLINE: HIV Infections, Anti-HIV Agents, Anti-Retroviral Agents. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NHLBI NIH HHS, NIAAA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While people with human immunodeficiency virus (PWH) start antiretroviral treatment (ART) regardless of CD4 count, CD4 measurement remains crucial for detecting advanced human immunodeficiency virus (HIV) disease and evaluating ART programs. We explored CD4 measurement (proportion of PWH with a CD4 result available) and prevalence of CD4 <200 cells/µL (hereafter “CD4 <200”) at ART initiation within the International epidemiology Databases to Evaluate AIDS (IeDEA) global collaboration.

Methods

We included PWH at participating ART programs who first initiated ART at age 15–80 years during 2005–2019. We described proportions of PWH with a CD4 result (measured within 6 months before to 2 weeks after ART initiation) and, among those with a CD4 result, with CD4 <200, by year of ART initiation and region.

Results

We included 1 355 104 PWH from 42 countries in 7 regions; 63% were female. The median (interquartile range) age at ART initiation was 37 (3144) years in males and 32 (26–39) years in females. CD4 measurement initially increased, or remained stable over time until around 2013, but then declined to low levels in some regions (Southern Africa, except South Africa: from 54% to 13%; East Africa: 85% to 31%; Central Africa: 72% to 20%; West Africa: 91% to 53%; and Latin America: 87% to 56%). Prevalence of CD4 <200 declined over time in all regions, but plateaued after 2015 at ≥30%.

Conclusions

CD4 measurement has declined sharply in recent years, especially in sub-Saharan Africa. Among those with a CD4 measurement, the prevalence of CD4 <200 remains concerningly high. Scaling up CD4 testing and securing adequate funding are urgent priorities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsAnti-HIV AgentsAnti-Retroviral AgentsHumansCD4 Lymphocyte CountMaleAdultFemaleMiddle AgedAdolescentYoung AdultAgedGlobal HealthAged, 80 and overPrevalence

Stichwörter der Autor:innen

Advanced HIV diseaseCD4 at ART startGlobal testing trendsHIV careTreat-All

Substanzen

Anti-HIV AgentsAnti-Retroviral Agents

Autor:innen und Institutionen

  • Centre for Infectious Disease Epidemiology and Research, School of Public Health, University of Cape Town, Observatory, South Africa.
  • Department of Medicine, Indiana University School of Medicine, Indianapolis.
  • Institute for Implementation Science in Population Health, City University of New York, New York.
  • Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.
  • National Institute for Health and Medical Research UMR 1219, Research Institute for Sustainable Development EMR 271, Bordeaux Population Health Research Centre, University of Bordeaux, France.
  • Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee.

ORCID-Profile: Reneé de Waal, Ellen Brazier, Keri N Althoff, Antoine Jaquet, Stephany N Duda, Helen Byakwaga, Gad Murenzi, Amy Justice, Mark K U Pasayan, Pelagie Babakazo, Claudia P Cortes, Jun Yong Choi, Jessica L Castilho, Nathan Ford, Reshma Kassanjee

Förderung

  • NIAID NIH HHS
  • NHLBI NIH HHS
  • NIAAA NIH HHS
  • NIMH NIH HHS
  • FIC NIH HHS
  • NIA NIH HHS
  • Emory Center for AIDS Research
  • NCI NIH HHS

Zitieren

APA

de Waal, R., Wools-Kaloustian, K., Brazier, E., Althoff, K. N., Jaquet, A., Duda, S. N., Kumarasamy, N., Savory, T., Byakwaga, H., Murenzi, G., Justice, A., Ekouevi, D. K., Cesar, C., Pasayan, M. K. U., Thawani, A., Kasozi, C., Babakazo, P., Karris, M., Messou, E., …, & Kassanjee, R. (2025). Global Trends in CD4 Count Measurement and Distribution at First Antiretroviral Treatment Initiation. Clinical Infectious Diseases, 80(6), 1332-1336. https://doi.org/10.1093/cid/ciae548

Vancouver

de Waal R, Wools-Kaloustian K, Brazier E, Althoff KN, Jaquet A, Duda SN, et al. Global Trends in CD4 Count Measurement and Distribution at First Antiretroviral Treatment Initiation. Clinical Infectious Diseases. 2025;80(6):1332-1336. doi:10.1093/cid/ciae548

BibTeX
@article{deWaal2025,
  author = {de Waal, Reneé and Wools-Kaloustian, Kara and Brazier, Ellen and Althoff, Keri N and Jaquet, Antoine and Duda, Stephany N and Kumarasamy, Nagalingeswaran and Savory, Theodora and Byakwaga, Helen and Murenzi, Gad and Justice, Amy and Ekouevi, Didier K and Cesar, Carina and Pasayan, Mark K U and Thawani, Agness and Kasozi, Charles and Babakazo, Pelagie and Karris, Maile and Messou, Eugene and Cortes, Claudia P and Kunzekwenyika, Cordelia and Choi, Jun Yong and Owarwo, Noela C and Niyongabo, Annabelle and Marconi, Vincent C and Ezechi, Oliver and Castilho, Jessica L and Petoumenos, Kathy and Johnson, Leigh F and Ford, Nathan and Kassanjee, Reshma},
  title = {Global Trends in CD4 Count Measurement and Distribution at First Antiretroviral Treatment Initiation},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  volume = {80},
  number = {6},
  pages = {1332--1336},
  doi = {10.1093/cid/ciae548}
}
Kostenlos starten →